Celiac Disease Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | AMYRA Biotech AG, Equillium Bio., Chugai Pharma, Calypso Biotech

Celiac Disease Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | AMYRA Biotech AG, Equillium Bio., Chugai Pharma, Calypso Biotech
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Celiac Disease pipeline constitutes 25+ key companies continuously working towards developing 25+ Celiac Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Celiac Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.


Celiac Disease Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Celiac Disease Market.


Some of the key takeaways from the Celiac Disease Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Celiac Disease treatment therapies with a considerable amount of success over the years. 
  • Celiac Disease companies working in the treatment market are AMYRA Biotech AG, Equillium Bio., Chugai Pharmaceutical Co., Ltd., Calypso Biotech, ImmunogenX, Inc., Amgen Inc., and others, are developing therapies for the Celiac Disease treatment 
  • Emerging Celiac Disease therapies in the different phases of clinical trials are- AMY02, EQ102, DONQ52, CALY-002, Latiglutenase, Ordesekimab, and others are expected to have a significant impact on the Celiac Disease market in the coming years.   
  • In April 2021, A Phase II, single-center prospective, double-blind, placebo-controlled, crossover trial was started by ImmunogenX in people with Type 1 diabetes and celiac disease who had been attempting a GFD for at least a year before screening. Seropositive participants (blood test results verified at Visit 0) will be scheduled for a Screening Visit (Visit 1), whereas seronegative participants would be removed from the research (screen failures).
  • Calypso Biotech reported that the first cohort of healthy patients in the initial Phase 1 clinical trial of CALY-002 for Celiac disease and Eosinophilic Esophagitis has finished receiving their doses.
  • In February 2020, Following the Phase I Celiac disease research findings of TAK-062, also known as Kuma062, Takeda bought PvP Biologics for $330M.


Celiac Disease Overview

The World Gastroenterology Organisation (WGO) defines Celiac disease as a chronic, multiple-organ small intestinal immune-mediated enteropathyprecipitated by exposure to dietary gluten in genetically predisposed individuals. It is also known as coeliac disease/non-tropical sprueor gluten-sensitive enteropathy.


Get a Free Sample PDF Report to know more about Celiac Disease Pipeline Therapeutic Assessment-



Emerging Celiac Disease Drugs Under Different Phases of Clinical Development Include:

  • AMY02 : AMYRA Biotech AG
  • EQ102 : Equillium Bio.
  • DONQ52 : Chugai Pharmaceutical Co., Ltd.
  • CALY-002 : Calypso Biotech
  • Latiglutenase : ImmunogenX, Inc.
  • Ordesekimab : Amgen Inc.


Celiac Disease Route of Administration

Celiac Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal
  • Molecule Type


Celiac Disease Molecule Type

Celiac Disease Products have been categorized under various Molecule types, such as

  • Oligonucleotide
  • Peptide
  • Small molecule 


Celiac Disease Pipeline Therapeutics Assessment

  • Celiac Disease Assessment by Product Type
  • Celiac Disease By Stage and Product Type
  • Celiac Disease Assessment by Route of Administration
  • Celiac Disease By Stage and Route of Administration
  • Celiac Disease Assessment by Molecule Type
  • Celiac Disease by Stage and Molecule Type


DelveInsight’s Celiac Disease Report covers around 25+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Further Celiac Disease product details are provided in the report. Download the Celiac Disease pipeline report to learn more about the emerging Celiac Disease therapies


Some of the key companies in the Celiac Disease Therapeutics Market include:

Key companies developing therapies for Celiac Disease are – 9 Metres Biopharma, Amgen, Allero Therapeutics, Takeda, Calypso Biotech, Anokion, Zedira GmbH, Millennium Pharmaceuticals, ImmunogenX, GlaxoSmithKline, ImmusanT, ActoBio Therapeutics, Amyra biotech, and others.


Celiac Disease Pipeline Analysis:

The Celiac Disease pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Celiac Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Celiac Disease Treatment.
  • Celiac Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Celiac Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Celiac Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Download Sample PDF Report to know more about Celiac Disease drugs and therapies


Celiac Disease Pipeline Market Drivers

  • Increasing prevalence of Celiac Disease, increasing R&D activities, no Approved Therapy are some of the important factors that are fueling the Celiac Disease Market.


Celiac Disease Pipeline Market Barriers

  • However, limited patient awareness about the disease, poor Patient Compliance and other factors are creating obstacles in the Celiac Disease Market growth.


Scope of Celiac Disease Pipeline Drug Insight    

  • Coverage: Global
  • Key Celiac Disease Companies: AMYRA Biotech AG, Equillium Bio., Chugai Pharmaceutical Co., Ltd., Calypso Biotech, ImmunogenX, Inc., Amgen Inc., and others
  • Key Celiac Disease Therapies: AMY02, EQ102, DONQ52, CALY-002, Latiglutenase, Ordesekimab, and others
  • Celiac Disease Therapeutic Assessment: Celiac Disease current marketed and Celiac Disease emerging therapies
  • Celiac Disease Market Dynamics: Celiac Disease market drivers and Celiac Disease market barriers 


Request for Sample PDF Report for Celiac Disease Pipeline Assessment and clinical trials


Table of Contents 

1. Celiac Disease Report Introduction

2. Celiac Disease Executive Summary

3. Celiac Disease Overview

4. Celiac Disease- Analytical Perspective In-depth Commercial Assessment

5. Celiac Disease Pipeline Therapeutics

6. Celiac Disease Late Stage Products (Phase II/III)

7. Celiac Disease Mid Stage Products (Phase II)

8. Celiac Disease Early Stage Products (Phase I)

9. Celiac Disease Preclinical Stage Products

10. Celiac Disease Therapeutics Assessment

11. Celiac Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Celiac Disease Key Companies

14. Celiac Disease Key Products

15. Celiac Disease Unmet Needs

16 . Celiac Disease Market Drivers and Barriers

17. Celiac Disease Future Perspectives and Conclusion

18. Celiac Disease Analyst Views

19. Appendix

20. About DelveInsight



About DelveInsight


DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services